Results 191 to 200 of about 13,205 (231)

ESTRO meetings

Radiotherapy and Oncology, 1995
  +12 more sources

ESTRO meetings

Radiotherapy and Oncology, 1996
  +12 more sources

ESTRO/ESGO/SIOPe Guidelines for the management of patients with vaginal cancer

International Journal of Gynecological Cancer, 2023
Primary vaginal malignancies are rare, comprising only 2% of all female genital tract malignancies in adults and 4.5% in children. As part of its mission to improve the quality of care for women with gynecological cancers across Europe, the European ...
Remi A. Nout, G. Calaminus, F. Planchamp, C. Chargari, S. Lax, H. Martelli, W. McCluggage, P. Morice, M. Pakiž, M. Schmid, Jonáh Stunt, B. Timmermann, Christian Vokuhl, D. Orbach, C. Fotopoulou   +14 more
semanticscholar   +1 more source

AAPM WGDCAB Report 372: A joint AAPM, ESTRO, ABG, and ABS report on commissioning of model‐based dose calculation algorithms in brachytherapy

Medical Physics (Lancaster), 2023
The introduction of model‐based dose calculation algorithms (MBDCAs) in brachytherapy provides an opportunity for a more accurate dose calculation and opens the possibility for novel, innovative treatment modalities.
L. Beaulieu, F. Ballester, D. Granero, Å. Tedgren, A. Haworth, J. Lowenstein, Yunzhi Ma, F. Mourtada, P. Papagiannis, M. Rivard, F. Siebert, Ron S. Sloboda, Ryan Smith, R. Thomson, F. Verhaegen, G. Fonseca, J. Vijande   +16 more
semanticscholar   +1 more source

EORTC/ESTRO defined induced oligopersistence of liver metastases from colorectal cancer - outcomes and toxicity profile of computer tomography guided high-dose-rate brachytherapy

Clinical and Experimental Metastasis
Colorectal cancer (CRC) often leads to liver metastases, which may be resistant to systemic therapy. This study assessed outcomes and toxicity of computed tomography (CT) guided high-dose-rate (HDR) brachytherapy (BRT) in oligopersistent liver metastases
P. Cisek, M. Bilski, Julia Ponikowska, Ewa Wojtyna, J. Fijuth, Łukasz Kuncman   +5 more
semanticscholar   +1 more source

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.

European Urology, 2020
N. Mottet, R. V. D. van den Bergh, E. Briers, T. Van den Broeck, M. Cumberbatch, M. De Santis, S. Fanti, N. Fossati, G. Gandaglia, S. Gillessen, N. Grivas, J. Grummet, A. Henry, T. H. van der Kwast, T. Lam, M. Lardas, M. Liew, M. Mason, L. Moris, D. Oprea-Lager, H. G. van der Poel, O. Rouvière, I. Schoots, D. Tilki, T. Wiegel, P. Willemse, P. Cornford   +26 more
semanticscholar   +1 more source

Estro-Androgenic Disrupting Effects of Halogenated Disinfection Byproducts: A Comprehensive Evaluation and Comparison.

Environmental Science and Technology
Drinking water halogenated disinfection byproducts (DBPs) have become an increasing health concern. However, the endocrine-disrupting effects of DBPs have not been well evaluated, and the limited available data have inhibited a comprehensive ...
Xueyao Chen, Yaoming Ge, Wei Shi, Mengting Yang, Qing Zhou, Yang Pan   +5 more
semanticscholar   +1 more source

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.

The Lancet Oncology, 2023
S. Kroeze, M. Pavic, K. Stellamans, Y. Lievens, C. Becherini, M. Scorsetti, F. Alongi, U. Ricardi, B. Jereczek-Fossa, P. Westhoff, J. But-Hadžić, J. Widder, X. Geets, S. Bral, M. Lambrecht, C. Billiet, I. Sirák, S. Ramella, Ivaldi Giovanni Battista, S. Benavente, A. Zapatero, F. Romero, T. Zilli, K. Khanfir, H. Hemmatazad, B. De Bari, Desiree N Klass, S. Adnan, H. Peulen, J. Salinas Ramos, M. Strijbos, S. Popat, P. Ost, M. Guckenberger   +33 more
semanticscholar   +1 more source

ESTRO 2023

The Lancet Oncology, 2023
openaire   +2 more sources